Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease

Kidney International

Volumn 83, Issue 5, 2013, Pages 909-914

  Liu, Kathleen D ^a   Yang, Wei ^b   Anderson, Amanda H ^b   Feldman, Harold I ^b   Demirjian, Sevag ^c   Hamano, Takayuki ^b   He, Jiang ^d   Lash, James ^e   Lustigova, Eva ^d   Rosas, Sylvia E ^b   Simonson, Michael S ^f   Tao, Kaixiang ^b   Hsu, Chi Yuan ^a,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d TULANE UNIVERSITY   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DIVISION OF RESEARCH   (United States)

Author keywords

chronic kidney disease; chronic renal failure; progression of chronic renal failure

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA;

EID: 84877031005     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.458     Document Type: Article

References (27)

1. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009; 5: 677-689.
2. Fassett RG, Venuthurupalli SK, Gobe GC et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-821.
3. Bolignano D, Donato V, Coppolino G et al. Neutrophil gelatinaseassociated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008; 52: 595-605.
4. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 127-132.
5. Brunner HI, Mueller M, Rutherford C et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhoodonset systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2577-2584.
6. Ding H, He Y, Li K et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 2007; 123: 227-234.
7. Bolignano D, Coppolino G, Campo S et al. Neutrophil gelatinaseassociated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol 2007; 27: 373-378.
8. Bolignano D, Coppolino G, Campo S et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 2008; 23: 414-416.
9. Suzuki M, Wiers KM, Klein-Gitelman MS et al. Neutrophil gelatinaseassociated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol 2008; 23: 403-412.
10. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H et al. Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant Proc 2009; 41: 158-161.
11. Viau A, El Karoui K, Laouari D et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010; 120: 4065-4076.
12. Wu Y, Su T, Yang L et al. Urinary neutrophil gelatinase-associated lipocalin: a potential biomarker for predicting rapid progression of druginduced chronic tubulointerstitial nephritis. Am J Med Sci 2010; 339: 537-542.
13. Bolignano D, Lacquaniti A, Coppolino G et al. Neutrophil gelatinaseassociated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 337-344.
14. Peters HP, Waanders F, Meijer E et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. Nephrol Dial Transplant 2011; 26: 3581-3588.
15. Nielsen SE, Andersen S, Zdunek D et al. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 2011; 79: 1113-1118.
16. Nielsen SE, Hansen HP, Jensen BR et al. Urinary neutrophil gelatinaseassociated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study. Nephron Clin Pract 2011; 118: c130-c135.
17. Parikh CR, Dahl NK, Chapman AB et al. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int 2012; 81: 784-790.
18. Nauta FL, Bakker SJ, van Oeveren W et al. Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. Am J Kidney Dis 2011; 57: 733-743.
19. Feldman HI, Appel LJ, Chertow GM et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol 2003; 14: S148-S153.
20. Lash JP, Go AS, Appel LJ et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009; 4: 1302-1311.
21. Levey AS, Coresh J, Greene T et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772.
22. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908-1919.
23. Hsu CY, Iribarren C, McCulloch CE et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169: 342-350.
24. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6: 356-365.
25. Gansevoort RT, Matsushita K, van der VeldeM et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80: 93-104.
26. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61: 92-105.
27. Pencina MJ, D'Agostino RB Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.